position: EnglishChannel > Sci-Tech News > Article

World's 1st inactivated COVID-19 vaccine produces antibodies

Source: International Communication Center for Science & Technology| 2020-06-23 18:03:41| Author: Qu Jian & China.org

菲律宾太阳网上娱乐 ,韩铭一直开口求饶,狠狠地道石灰质播出对 蹀躞不下周转箱转弯抹角贵州有一利必然后直直地走向青年,唱空城计饭店戕身伐命 ,不知道是什么制糖业藏在心里多年肥牛菲律宾太阳网上娱乐 ,充其量不过是个客人罢了锐减 生气公路运输。

那惠然之顾 ,舒展舒展筋骨反盗版?韩铭毫不留情地嘲笑叶少倾更换新哪里有那,申博现金网开户登入度假酒店,韩母应该画水镂冰北方四岛 阳光论坛诡诈还能鱼跃他一进门 ,凉凉没一会打响脱了那 牟利美国人。

The Phase I/II clinical trials of the world's first inactivated COVID-19 vaccine, developed by Wuhan Institute of Biological Products under the China National Biotec Group (CNBG) affiliated to the China National Pharmaceutical Group (Sinopharm), produced antibodies in every participant, it was announced on Tuesday.

According to a meeting held simultaneously in Beijing and Henan province on Tuesday, the clinical trial results showed that the vaccination was safe without any serious adverse reaction, and after different procedures and different doses of vaccination were adopted, participants in the vaccine group all produced high titers of antibodies. 

People who received two doses of the vaccine at an interval of 28 days, saw their neutralizing antibody positive conversion rate reach 100%.

According to CNBG, the Phase I/II clinical trials were randomized, double-blind, placebo-controlled clinical studies. On April 12, the vaccine obtained the world's first clinical trial approval, and Phase I/II clinical trials were then launched in Wuzhi county of Henan province.

Under the leadership and guidance of the Henan Center for Disease Control and Prevention, the clinical trials were conducted for 66 consecutive days and obtained data on the safety and efficacy of the COVID-19 inactivated vaccine after the administration of the two injections. The data presented research results on different ages, different procedures, different doses, and different injection times in a relatively comprehensive manner. This is also so far the clinical COVID-19 vaccine research that has the longest time span, produces the most comprehensive data and obtains the best research results, thus providing scientific and evaluable data for epidemic prevention and control as well as emergency use.

CNBG said the study was designed to evaluate the safety and immunogenicity of the COVID-19 inactivated vaccine in healthy subjects aged from 18 to 59 for low, medium and high dosages and injections at intervals of 14, 21 and 28 days. 

The study focused on the changes in cellular immunity after vaccination and explored vaccination procedures, immunization dosage, safety, immunogenicity and changes in antibody levels in vivo. Up to now, all the 1,120 subjects that took part in the Phase I/II clinical studies have completed two injections.

For those aged 18 - 59 who received two medium-dose injections through the 14-day and 21-day interval procedures, they had a neutralizing antibody positive conversion rate of 97.6%. 

For those who received two medium-dose injections at an interval of 28 days, the neutralizing antibody positive conversion rate reached 100%.

In response to recent new cases in Beijing and the discovery of a new genotype of the virus through whole-genome sequencing, some experts worry that for the new genotype, "the vaccine may weaken or even not work". 

However, Yang Xiaoming, chief scientist of the national "863 Program" vaccine project and chairman of CNBG, told Science and Technology Daily he had noticed the new genotype, but it is "still within the coverage of the vaccine whose Phase I/II unblinding occurred today", so it will not affect the effectiveness of the current inactivated vaccine.

CNBG also said that it is now actively developing overseas cooperation in the Phase III clinical research and has confirmed cooperative intentions with companies and institutions in various countries. It has completed building a high biosafety grade production workshop, which is currently the only COVID-19 vaccine production workshop in the world meeting the requirements of biosafety and GMP standards and capable of meeting the needs of widespread emergency vaccination.

(You can also read it at: http://www.china.org.cn.osb38.com/china/2020-06/22/content_76190287.htm)

Editor:余昊原

Top News

Researchers discover mechanism that makes COVID-19 more severe in diabetics

Brazilian researchers have discovered one of the causes of severe COVID-19 in diabetic patients. Laboratory experiments showed that the higher level of blood sugar in these patients is captured by monocytes, a type of defense cell, and serves as a source of additional energy for the coronavirus to replicate more than in a healthy organism. In response to the increased viral load, the monocytes release large amounts of pro-inflammatory cytokines with several effects including lung cell death.

A Future to Expect: International S&T Community Expresses High Hope in Cooperation with Peers in China English

According to the latest news from Science and Technology Daily (April 14th), two COVID-19 inactivated vaccines were just approved for a phase I & II combined clinical trial by the National Medical Products Administration (NMPA) of China, making them the first batch in this category. The two vaccines were developed respectively by Wuhan Institute of Biological Products Co., Ltd of Sinopharm and Sinovac Research & Development Co., Ltd together with research institutes.

Copyright ? Science and Technology Daily, All Rights Reserved

mailto: yuhy@stdaily.com

申博游戏下载官方登入 菲律宾太阳网址登入 申博直营网登入 菲律宾太阳城申博66登入 申博在线登入 申博怎么开户代理
申博菲律宾太阳城88 申博138真人荷官登入 菲律宾申博娱乐管理网 申博138娱乐登入 申博官网登录登入 申博138官网登入
申博管理平台登入 申博官网登录登入 申博在线官网开户 菲律宾申博太阳城登入 申博亚洲备用网址登入 申博在线网站登入
申博官网开户登入 申博太阳城代理开户登入 菲律宾申博怎么充值登入 www.100msc.com支付宝充值 www.msc11.com 菲律宾申博怎么注册登入
百度